Investing in the interpretation layer of medicine.
Sequencing is commoditising; interpretation is the durable, defensible layer. This is the thesis behind Soma Nova, and where capital is deployed to build it.
Whoever owns the trusted, explainable interpretation of the genome owns the most durable position in genomic medicine. That is the layer we are building.
Series A.
Soma Nova is raising a Series A to take the platform through clinical validation and registration in its first indication, and into market in India and the UK. Target, structure and terms are shared with qualified investors under NDA.
Raise size, structure and valuation
Target, equity, financial model, detailed use of funds and traction are shared through the data room with investors who qualify under the applicable exemptions.
Request the data roomWhere the capital goes.
Platform & product
Deepen the interpretation engine, the eleven-layer Digital Twin and the three product layers.
Clinical validation
Anchor-site pilots generating evidence in rare disease, oncology and pharmacogenomics.
Regulatory & compliance
CDSCO and UKCA pathways, certifications, and BODH benchmark submission.
Go-to-market
Commercial motion across India and the UK.
Team
Founding hires across clinical genomics, AI and engineering.
Interoperability
FHIR/GA4GH and ABDM integration with health-system partners.
From anchor sites to scale.
Partner deployments in India and the UK — defined case volume, named reviewers, structured feedback.
Concordance and turnaround data across rare disease, oncology and pharmacogenomics; BODH benchmark entry.
Expand solutions and health-system integrations; open the US horizon.
Request the data room.
Detailed materials, financials, raise terms and traction are available to qualified investors under NDA. Tell us who you are and we will verify eligibility before sharing.